Project Grant W81XWH2210194

The University of California, Irvine (UCI) was awarded a $785,000 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on an "Endocannabinoid Deficit in Brain Neuroinflammatory Control as a Therapeutic Target for Gulf War Illness." This 3-year research project, commencing on June 15, 2025, aims to investigate potential medical treatments for Gulf War Illness by exploring the role of the endocannabinoid system...

The Defense Health Agency awarded a $749,905 Project Grant to The Roskamp Institute Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2023 through September 2026 to investigate microglial NOX2/NLRP3 inflammasome activation and its role in driving tau pathology and cognitive impairments in chronic traumatic brain injury. Specifically, the Roskamp Institute will conduct basic, applied, and advanced biomedical...

This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $713,277 to Boston University Medical Campus to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness. The award will support the project from September 1, 2024 through August 31, 2027. As part of this...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $258,213 to Reelin Therapeutics, Inc. to identify the next generation of gamma-secretase modulators for the treatment of Alzheimer's disease. The research aims to develop novel lead compounds that can lower amyloid-beta 42 production, a key driver of amyloid plaque formation, while avoiding effects on other gamma-secretase substrates like Notch. Through medicinal chemistry and in vitro/in vivo...

This federal Project Grant award of $414,953 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is focused on understanding the role of inflammasomes, which are protein complexes that induce inflammatory responses, in driving sexual dimorphism in glioma therapies. The key objectives are to determine whether inhibiting the NLRP3 inflammasome can overcome...

This Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The goal of the project is to test whether a new humanized monoclonal antibody (ADWA11) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). The $254,896 award to Glial Therapeutics, LLC will support research to understand how pharmacological inhibition of the ITGB8 integrin can modulate microglia phenotype and function to...

The U.S. Defense Health Agency awarded a $817,200 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Roskamp Institute, Inc. in Sarasota, Florida. The grant, awarded on September 1, 2024, will support a 3-year research project titled "Targeting APOE Bioenergetics for Reducing the Risk of Neurodegeneration After Chronic Traumatic Brain Injury." The research aims to investigate mitochondrial bioenergetics, tau protein pathology,...

This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,268,799.00 to The Roskamp Institute, Inc. to conduct research on the therapeutic effects of a novel blood-brain barrier-penetrating PPAR agonist for improving chronic outcomes following age-related repetitive mild traumatic brain injury. The award period runs from Sep 15, 2025 to Sep 14, 2029. The Roskamp Institute, a non-profit biotechnology research...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,830,581 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Johns Hopkins University. The grant supports in-depth characterization of the mechanism of action of a new macrocycle molecule called RAPIREON, which selectively activates the nuclease activity of the IRE1 protein in the unfolded protein response (UPR) pathway....

This Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), provides $1,704,652.00 to Trustees of Boston University (Boston University Medical Campus) to conduct research on the translational impact of genetic susceptibility to complex toxic exposures on blood-brain barrier function and age-related neurological outcomes in Gulf War Illness (GWI). The award period runs from September 1, 2024 to August...